NCT03425812 is a NA clinical trial of To withdraw NSAIDs therapy in Axial Spondyloarthritis, sponsored by The First Affiliated Hospital of Xiamen University.

Who is sponsoring NCT03425812?

NCT03425812 is sponsored by The First Affiliated Hospital of Xiamen University.

What drugs are being tested in NCT03425812?

Interventions in NCT03425812: To withdraw NSAIDs therapy, To continue NSAIDs therapy.

What condition does NCT03425812 study?

NCT03425812 studies Axial Spondyloarthritis.

Is NCT03425812 still recruiting?

NCT03425812 is currently recruiting now. Last updated 18 April 2022.

Last reviewed 2022-04-18 · How we verify

NCT03425812

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission

Recruiting now NA Last updated 18 April 2022

What this trial tests

NA trial testing To withdraw NSAIDs therapy in Axial Spondyloarthritis in 140 participants. Currently enrolling.

Timeline

15 February 2018

Primary endpoint
20 December 2025

20 December 2028

Quick facts

Lead sponsor	The First Affiliated Hospital of Xiamen University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	140
Start date	15 February 2018
Primary completion	20 December 2025
Estimated completion	20 December 2028
Sites	1 location across China

Drugs / interventions tested

To withdraw NSAIDs therapy — full drug profile →
To continue NSAIDs therapy — full drug profile →

Conditions studied

Axial Spondyloarthritis — all drugs for Axial Spondyloarthritis →

Sponsor

The First Affiliated Hospital of Xiamen University

Who can join

18 and older, any sex, with Axial Spondyloarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The multicenter, randomized controlled trial is to investigate and evaluate the effect of NSAIDs therapy on recurrence in patients with axial spondyloarthritis;

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Predictive Value of Active Sacroiliitis in MRI for Flare Among Chinese Patients with Axial Spondyloarthritis in Remission.
Zheng Q, Liu W, Huang Y, Gao Z, et al · · 2021 · cited 5× · PMID 33598865 · DOI 10.1007/s40744-021-00279-y
The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis.
Cai M, Liu W, Wu Y, Zheng Q, et al · · 2022 · cited 2× · PMID 35897055 · DOI 10.1186/s12891-022-05657-3

Verify or expand the search:

Other recruiting trials for Axial Spondyloarthritis

Currently open trials in the same condition.

NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
NCT07414823 — Walking Football for Axial Spondyloarthritis · NA · active not recruiting
NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting

Other The First Affiliated Hospital of Xiamen University trials

Trials by the same sponsor.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03425812 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
Last refreshed: 18 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03425812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing